| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A career development programme for women at an academic medical centre
|
Orlov, Marika
|
|
|
13 |
2 |
p. e9
|
article
|
| 2 |
Associations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies
|
Perret, Jennifer L
|
|
|
13 |
2 |
p. 130-140
|
article
|
| 3 |
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges
|
van Boven, Job F M
|
|
|
13 |
2 |
p. 177-188
|
article
|
| 4 |
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study
|
Xu, Jin-Fu
|
|
|
13 |
2 |
p. 166-176
|
article
|
| 5 |
Bronchiectasis in China: increasing awareness and action
|
Huang, Ke
|
|
|
13 |
2 |
p. 108-109
|
article
|
| 6 |
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021–23)
|
Hak, Sarah F
|
|
|
13 |
2 |
p. 153-165
|
article
|
| 7 |
Chronic cough as a disease: implications for practice, research, and health care
|
Chung, Kian Fan
|
|
|
13 |
2 |
p. 110-112
|
article
|
| 8 |
Clean air, climate targets, and respiratory health in Europe
|
Balakrishnan, Vijay Shankar
|
|
|
13 |
2 |
p. e12-e13
|
article
|
| 9 |
Collateral caring
|
Wu, Hemmings
|
|
|
13 |
2 |
p. 116-117
|
article
|
| 10 |
Correction to Lancet Respir Med 2025; 13: 141–52
|
|
|
|
13 |
2 |
p. e11
|
article
|
| 11 |
Elucidating the outpatient burden of RSV disease in children
|
Dawood, Fatimah S
|
|
|
13 |
2 |
p. 106-108
|
article
|
| 12 |
Expanding CFTR modulator access to benefit all patients who are waiting for a lung transplant
|
Brugha, Rossa
|
|
|
13 |
2 |
p. e10
|
article
|
| 13 |
First-line treatment for advanced NSCLC in older patients and those with poor performance status
|
Li, Ziming
|
|
|
13 |
2 |
p. 105-106
|
article
|
| 14 |
Margareth Dalcolmo: TB expert and Brazil's “face of COVID-19”
|
Kirby, Tony
|
|
|
13 |
2 |
p. 117-118
|
article
|
| 15 |
New territories: perioperative chemoimmunotherapy in early-stage NSCLC
|
Okuma, Yusuke
|
|
|
13 |
2 |
p. 102-103
|
article
|
| 16 |
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
|
Léna, Hervé
|
|
|
13 |
2 |
p. 141-152
|
article
|
| 17 |
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
|
Yue, Dongsheng
|
|
|
13 |
2 |
p. 119-129
|
article
|
| 18 |
PH and CKD: unravelling the cardiorenal nexus
|
Husain-Syed, Faeq
|
|
|
13 |
2 |
p. 112-115
|
article
|
| 19 |
Respiratory research funding: consequences of neglect
|
The Lancet Respiratory Medicine,
|
|
|
13 |
2 |
p. 101
|
article
|
| 20 |
Respiratory symptoms and lung function trajectories: does wheeze hold the answer?
|
Whittaker, Hannah
|
|
|
13 |
2 |
p. 103-104
|
article
|
| 21 |
Thank you to The Lancet Respiratory Medicine's clinical and statistical peer reviewers in 2024
|
The Lancet Respiratory Medicine Editors,
|
|
|
13 |
2 |
p. e14-e16
|
article
|
Journal description